Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is a clinical-stage immuno-oncology company dedicated to developing novel immunotherapies that harness the body’s immune system to target and eradicate cancer. Originally founded in 2005 under the name Advaxis and rebranded as Ayala Pharmaceuticals in early 2024, the company specializes in a proprietary Lm-LLO (Listeria monocytogenes–listeriolysin O) based antigen delivery platform. This unique technology is designed to stimulate potent antigen-specific T-cell responses against a variety of solid tumors, including prostate, cervical and head and neck cancers.
The company’s pipeline includes several lead product candidates. ADXS-503 is being evaluated in combination with checkpoint inhibitors for metastatic castration-resistant prostate cancer, while ADXS-PSA and ADXS-HPV are in various stages of clinical development for prostate and HPV-associated malignancies, respectively. Each program leverages the company’s expertise in genetically attenuated Listeria vectors to present tumor-associated antigens and activate endogenous T cells, with the goal of improving response rates and long-term survival compared to standard of care immunotherapies.
Headquartered in Princeton, New Jersey, Ayala Pharmaceuticals conducts its clinical research across sites in North America and Europe, maintaining partnerships with leading academic institutions and global biopharmaceutical companies. The company also supports scalable manufacturing capabilities through strategic alliances in the United States and Asia, ensuring a reliable supply chain as its pipeline advances through late-stage trials.
Under the leadership of President and Chief Executive Officer Daniel Abdun-Nabi, Ayala combines scientific rigor with a patient-centric approach to accelerate the development of next-generation cancer therapies. The executive team brings together seasoned professionals in clinical development, regulatory affairs, and corporate strategy, all focused on delivering transformative immunotherapies to patients facing cancers with high unmet medical need.
AI Generated. May Contain Errors.
